Both yeasts and filamentous fungi have been identified as microbial pathogens in CF particularly in the context of invasive disease in the transplanted population and allergic responses, for instance allergic bronchopulmonary aspergillosis (ABPA). One particular fungal genus isolated at high frequencies from sputum culture is Candida and limited literature is available addressing the issues of Candida colonization and infection in CF. This is possibly because its manifestations are still considered relatively minor in comparison to other infectious agents. As a consequence it has received little attention in terms of clinical and scientific research. This review aims to provide an overview and our current understanding of the Candida species in CF, its associated local and systemic infections and an insight into emerging data on its role in airway colonization and associated immune response.
The Candida genus
Oral thrush was the first infection of the Candida species described in humans and following identification of its reproductive potential by budding, the fungus was originally named
Oidium albicans. Candida albicans became the adopted name used and since then many other species have been identified to play a role in human infection. The most common of Prior studies have addressed the notion that although frequently identified in CF, the clinical role of Candida species has yet to be definitively determined (6) (7) (8) . Bakare et al identified
Candida as the second most frequent fungal growth to Aspergillus in the CF airway and such growth has been associated with more severe CF where patients receive prolonged treatment with antibiotics, glucocorticoids and probiotics (9) (10) (11) (12) . In terms of infection, Cimon et al performed a five-year epidemiological study assessing the frequency of bronchopulmonary mycoses in a CF population and examined the aetiological role of individual fungal species in disease. The filamentous fungi Aspergillus and Scedosporium apiospermum together with
Candida contributed the largest burden. Despite high isolation of Candida in CF, a single case of candidiasis was observed and this low rate was attributed to the anti-fungal ability of various bacterial colonizers in CF and whilst invasive airway infection is a rare event, extent of airway damage from hypersensitivity phenomena remain unknown (13) . We will now address the localized and systemic infections associated with Candida species in CF and subsequently tackle the complex issues of airway colonization, cross kingdom interaction and the immune response.
Localized Candida infection in CF

Oral candidiasis
Candida species are isolated from the oral mucosa in up to 40% of healthy adults and therefore considered commensal (14) . A cut-off point to distinguish between commensalism and colonization remains undetermined. questioning of major symptoms in the CF population, 40% (n=17) complained of a sore mouth, 24% (n=10) of thrush five times annually and 38% (n=16) of a hoarse voice every three months (15) . In our own institution's experience, we encounter regular instances of oral candidiasis annually following courses of antibiotics but which resolve after a short burst of anti-fungal treatment (Fluconazole). We recommend microbiological confirmation by scrapings in all cases unless white plaques are directly observed on oral examination. This is because some of the symptoms described are not specific to oral thrush but can be found in associated vitamin deficiencies (B 6 , B 12 ) or by simple blistering. We recommend that CF patients attending routine clinic be screened for risk factors and questioned at three-monthly intervals with regard to the symptoms of oral thrush including frequency of sore or dry mouth, crusting lips, dysphagia, dysphonia or hoarseness and difficulties with taste. Any relationship to antibiotic treatment should be teased out. Clearly oral candidiasis is recognized in CF but the dearth of available literature suggests it is probably misdiagnosed, ignored or missed in several cases. A simple risk factor and symptom screen would see 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Genital candidiasis
Genital candidiasis is a common occurrence in the normal population with rates of up to 75%
having single and 50% recurrent episodes (2 Bloodstream and other invasive infections secondary to Candida are rare and will not be addressed in any detail within this review except to state that when present occur within the first month following transplantation (22, 23) . This is primarily a consequence of the major surgical intervention and intensive care unit stay experienced by patients.
Totally implantable venous access device (TIVAD) infection
A more commonly encountered systemic infection associated with Candida involves the presence of a TIVAD commonly referred to as a "port". Candida species in this setting are recognized as the most common infecting organism associated with a TIVAD resulting in septicaemia (24-26). Important risk factors for infection remain the same as that for other Candida infections. Diagnosed by the presence of swinging pyrexia, systemic septicaemia and positive blood cultures for Candida species taken from both the port site and peripherally, the first intervention remains to remove the offending device whose tip should also be sent for microbiological evaluation. Device removal results in significant clinical improvement however aggressive anti-fungal therapy is concurrently administered during and systemic anti-fungal treatment dictated through sensitivity testing. Our own practice continues to evolve with regard to optimal treatment and we routinely look for at least two negative blood cultures following completion of the prescribed treatment course. Replacing ports depends on need but we try not to replace before 8 weeks following the last negative blood culture. To date, there remain no clinical trials or evidence based guidelines to support these treatment practices. Another important point is that many Candida infections involve biofilm formation particularly with indwelling vascular catheters in the context of CF. These biofilms are microbiologically complex containing matrix enclosed microcolonies containing yeasts and hyphae in a bilayer structure (27). Such Candida biofilms can be resistant to conventional anti-fungals through a multitude of mechanisms and as such future research needs to be conducted to determine the best and optimally standardized treatment of Candida port infections. Candida species was at least nine months and that the species identified were genetically related and transmissible but susceptible to all anti-fungals tested. Although concerns of transmissibility persist, it is unsure whether this species conclusively contributes to chronic infection and the inflammatory milieu in CF (28). We have assessed colonization rates at our own centre over prolonged time periods and found persistence rates in excess to that previously described. We have established that the main factors predicting colonization by
Candida albicans in CF are pancreatic insufficiency, osteopenia and co-colonization with
Pseudomonas. At first glance, this suggests that the more advanced a patient's disease, the likelier their sputum contained Candida albicans, a view of many clinicians and it may be that the organism acts as nothing more than a microbiological marker of disease severity in Newer airway Candida species have also emerged over the last decade and one pertinent example is the high recovery rates (10-25%) of C. dubliniensis from the oral cavity of HIV patients (30). This new organism was subsequently described in the non-HIV population particularly in individuals receiving high antibiotic burdens (31). Therefore, its detection in CF came as no surprise but did involve a complex isolation procedure involving Staib agar 
Candida-bacterial interactions
According to Costerton (35), biofilms are 'a structured community of bacterial cells enclosed in a self-produced polymeric matrix and adherent to an inert or living surface'. Traditionally biofilms have been thought to comprise a single bacterial species however it is now increasingly recognised that mixed biofilms exist involving interactions between both prokaryotes and eukaryotes. Bacteria and fungi are found together in a variety of environments but particularly in biofilms, where adherent species interact through diverse signaling mechanisms. In the host C. albicans can often be found growing with bacteria in polymicrobial biofilms and interspecies interactions occur that can impact on the transition of C. albicans between virulent and nonvirulent states (27). Under conditions of immune dysfunction, such as in the CF lung, colonising C. albicans can become an opportunistic The process of QS can cross the prokaryote-eukaryote boundary (36-39).
Interactions with Pseudomonas aeruginosa
Pseudomonas aeruginosa is the most prevalent opportunistic pathogen in individuals with CF and is the principal organism associated with biofilm formation in the CF lung; S. aureus and secreted QS factors and regulatory molecules such as rpoN (43) . By forming a biofilm on fungal filaments P. aeruginosa may be able to obtain nutrients from C. albicans in a nutritionally scarce environment. 
Interactions with Staphylococcus aureus
In oral biofilms a mutually beneficial interaction called coaggregation can occur where the adhesion of C. albicans to oral bacteria facilitates its colonization of the oral cavity (50) (51) (52) .
In contrast, the interaction between C. albicans and Pseudomonas aeruginosa as described above is competitive and antagonistic in nature. A third mechanism of interaction that can occur is that evident between staphylococci and C. albicans, which appears to be initially anti-bacterial factor. It remains to be seen which has the more detrimental effect in the CF lung, C. albicans growing alone or in combination with S. aureus in a mixed biofilm.
Interactions with other microbes
Notwithstanding the ability of C. albicans to modulate bacterial growth, reciprocal evidence
indicates that other bacteria may also play an important role in the pathogenesis of C.
albicans infections. For example in the urinary tract Escherichia coli can enhance adhesion of C. albicans to bladder mucosa (59) whereas in the gut indigenous microbes can inhibit mucosal adhesion of C. albicans (60) . Consequently alterations in the normal bacterial flora following treatment with broad-spectrum antibiotics may allow C. albicans to proliferate and invade tissues, greatly affecting its pathogenicity (60) . This is an important consideration for individuals with CF who are frequently prescribed antibiotics.
This may be most clearly studied in the oral cavity where adhesion of C. albicans to salivacoated surfaces and proline-rich proteins is an important early step in colonization (50, (61) (62) (63) 
Candida and the immune response
The outer strata of Candida species contain elements with antigenic potential. These include mannans and mannoproteins which upon human exposure induce an immunogenic response 
Innate immunity
Recognition of microbes by the innate immune system depends on activation of specific pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs). galectin-3 and TLR4 whereas complement receptor 3 (CR3), dectin-1 and TLR2 detect the β-glucans.
CLRs
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TLRs
Cell mediated immunity
Individuals whose cell mediated immunity is compromised are at an increased susceptibility of infection with Candida species illustrating the important role that this arm of the immune system plays in the host defence against the organism. The reasons underlying this observation remain ambiguous and little work has been performed in CF to examine this potential link. In non-CF animal models, interleukin (IL)-12 promotes a Th1 response to
Candida exposure and IL-10 systemic infection (102, 103) . In contrast interferon (IFN)-gamma appears to be protective (104). Allard et al have shown that CF oropharyngeal exposure to Candida lysates evoked a Th2 type immune response similar to that observed in non-CF models. However when exposed to both Pseudomonas and Candida lysates together a deviation in the adaptive immune response from a Th2 to Th1 type associated with neutrophilia is noted (105) . Neutrophils also damage pseudohyphae in association with IFNgamma to provide another host resistance strategy against Candida species. This is mediated through granulocyte colony stimulating factor (G-CSF) (106, 107) . Additionally, Dectin-1 by distinguishing cell wall β-glucan can trigger cell mediated defences (81) . While the cytokine mileu and neutrophil response in CF continue to be an area of intense investigation among researchers, minimal data to date remains accessible with regard solely to Candida species.
Humoral immunity
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